<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01175356</url>
  </required_header>
  <id_info>
    <org_study_id>ANBL09P1</org_study_id>
    <secondary_id>NCI-2011-01745</secondary_id>
    <secondary_id>CDR0000682629</secondary_id>
    <secondary_id>ANBL09P1</secondary_id>
    <secondary_id>ANBL09P1</secondary_id>
    <secondary_id>U10CA180886</secondary_id>
    <secondary_id>U10CA098543</secondary_id>
    <nct_id>NCT01175356</nct_id>
  </id_info>
  <brief_title>Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin</brief_title>
  <official_title>A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is studying induction therapy followed by meta-iodobenzylguanidine (MIBG)
      labeled with iodine-131 and chemotherapy in treating patients with newly diagnosed high-risk
      neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy
      with isotretinoin. Radioisotope therapy, such as MIBG labeled with iodine-131, releases
      radiation that kills tumor cells. Drugs used in chemotherapy, such as cisplatin, etoposide,
      busulfan, and melphalan, work in different ways to stop the growth of tumor cells, either by
      killing the cells or by stopping them from dividing. A peripheral stem cell transplant can
      replace blood-forming cells that are damaged by MIBG labeled with iodine-131 and
      chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To assess the feasibility of treating high-risk neuroblastoma patients, age 365 days - 30
      years, with a) an induction block of meta-iodobenzylguanidine labeled with iodine-131
      (131I-MIBG [iobenguane I 131]) delivered after multi-agent chemotherapy, and b)
      post-induction busulfan/melphalan (Bu/Mel) consolidation therapy.

      SECONDARY OBJECTIVES:

      I. To assess the tolerability of treating high-risk neuroblastoma patients, age 365 days - 30
      years, with a) an induction block of 131I-MIBG therapy delivered after multi-agent
      chemotherapy, and b) the tolerability of receiving post-induction Bu/Mel consolidation
      therapy with autologous stem-cell rescue (ASCR), and local radiation therapy.

      TERTIARY OBJECTIVES:

      I. To assess the response rate after a regimen of induction chemotherapy and 131I-MIBG and
      after a consolidation regimen of Bu/Mel with ASCR and local radiation therapy.

      II. To describe the relationship of tumor norepinephrine transporter (hNET) expression with
      radioiodinated MIBG uptake, at diagnosis as well as with tumor response.

      III. To assess the relative reliability of 123 I-MIBG and fludeoxyglucose F-18
      (18FDG)-positron emission tomography (PET) imaging in assessment of tumor activity at
      diagnosis, and prior to surgical resection.

      IV. To compare detectable tumor burden on the pre-surgical resection radioiodinated-MIBG
      diagnostic scan and the immediate post-MIBG therapy 131I-MIBG scan.

      V. To test for the relationship of occurrence of sinusoidal obstruction syndrome (SOS) to
      Bu/Mel or to whole-body radiation dose or delayed radiation clearance due to 131I-MIBG.

      VI. To analyze busulfan pharmacokinetics as measured by area under the curve (AUC) and relate
      exposure to SOS incidence.

      OUTLINE:

      INDUCTION CHEMOTHERAPY: Patients receive 5 courses of induction therapy.

      Courses 1-2: Patients receive cyclophosphamide intravenously (IV) over 15-30 minutes and
      topotecan hydrochloride IV over 30 minutes on days 1-5. Patients undergo peripheral blood
      stem cell (PBSC) collection after course 2.

      Course 3 and 5: Patients receive cisplatin IV over 1 hour on days 1-4 and etoposide phosphate
      IV over 1-2 hours on days 1-3. Patients undergo surgery to remove remaining tumor following
      course 5.

      Course 4: Patients receive cyclophosphamide IV over 1-6 hours on days 1-2 and vincristine
      sulfate IV over 1 minute and doxorubicin hydrochloride IV over 24 hours on days 1-3.

      Treatment repeats every 21 days for a total of 5 courses in the absence of disease
      progression or unacceptable toxicity. Patients without progressive disease proceed to
      iobenguane I 131 induction therapy beginning 3-6 weeks after course 5. Patients receive
      iobenguane I 131 IV over 90-120 minutes on day 1.

      SURGERY: Patients undergo surgery after course 4 or before consolidation therapy.

      CONSOLIDATION THERAPY: Within 10-12 weeks from the date of iobenguane I 131 infusion,
      patients receive busulfan IV over 2 hours every 6 hours on days -6 to -3 and melphalan IV on
      day -1.

      AUTOLOGOUS STEM CELL RESCUE: Patients undergo infusion of PBSC on day 0.

      RADIOTHERAPY: Beginning no sooner than 42 days after peripheral blood stem cell infusion,
      patients undergo 12 fractions of external-beam radiotherapy (2 dimensional [D], 3D-conformal,
      or intensity-modulated) to all areas of residual disease, primary tumor site, and involved
      nodal disease.

      MAINTENANCE THERAPY: Beginning 66 days after transplantation, patients receive isotretinoin
      orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 28 days for 6 courses.

      After completion of study therapy, patients are followed up every 3 months for 1 year, every
      6 months for 4 years, and then annually for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 28, 2016</completion_date>
  <primary_completion_date type="Actual">September 28, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131</measure>
    <time_frame>Up to 6 weeks after course 5 of induction</time_frame>
    <description>Number of MIBG avid patients who receive 131I-MIBG divided by the number of patients evaluable for the feasibility of MIBG endpoint x 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel Chemotherapy</measure>
    <time_frame>Up to day -6 of conditioning</time_frame>
    <description>Number of MIBG avid patients who receive 131I-MIBG and Bu/Mel divided by the number of patients evaluable for the feasibility of MIBG and Bu/Mel consolidation endpoint x 100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Unacceptable Toxicity and Sinusoidal Obstruction Syndrome (SOS), Assessed by Common Terminology Criteria (CTV)v.4.0 for Toxicity Assessment and Grading for I-MIBG</measure>
    <time_frame>Up to 6 weeks after course 5 of induction</time_frame>
    <description>Number of patients who had an unacceptable toxicity or experienced SOS. Unacceptable toxicity was defined as CTC Grade 4-5 Pulmonary/Respiratory.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Disseminated Neuroblastoma</condition>
  <condition>Ganglioneuroblastoma</condition>
  <condition>Localized Resectable Neuroblastoma</condition>
  <condition>Localized Unresectable Neuroblastoma</condition>
  <condition>Regional Neuroblastoma</condition>
  <condition>Stage 4S Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>CPM</other_name>
    <other_name>CTX</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Endoxan</other_name>
    <other_name>Endoxana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>hycamptamine</other_name>
    <other_name>Hycamtin</other_name>
    <other_name>SKF S-104864-A</other_name>
    <other_name>TOPO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>ETOP</other_name>
    <other_name>Etopophos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>leurocristine sulfate</other_name>
    <other_name>VCR</other_name>
    <other_name>Vincasar PFS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>ADM</other_name>
    <other_name>ADR</other_name>
    <other_name>Adria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>iobenguane I 131</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>131 I-MIBG</other_name>
    <other_name>I 131 Metaiodobenzylguanidine</other_name>
    <other_name>Iodine I 131 Metaiodobenzylguanidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>BSF</other_name>
    <other_name>BU</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeloleukon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>Alkeran</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-phenylalanine mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
    <description>Undergo autologous in vitro-treated peripheral blood stem cell transplantation</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
    <description>Undergo autologous in vitro-treated peripheral blood stem cell transplantation</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>in vitro-treated PBPC transplantation</other_name>
    <other_name>in vitro-treated PBSC</other_name>
    <other_name>in vitro-treated peripheral blood progenitor cell transplantation</other_name>
    <other_name>PBPC transplantation, in vitro-treated</other_name>
    <other_name>peripheral blood progenitor cell transplantation, in vitro-treated</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>3D conformal radiation therapy</other_name>
    <other_name>3D-CRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>external beam radiation therapy</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>EBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Undergo radiotherapy</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isotretinoin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>13-CRA</other_name>
    <other_name>Amnesteem</other_name>
    <other_name>Cistane</other_name>
    <other_name>Claravis</other_name>
    <other_name>Sotret</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (131I-MIBG, chemotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have a diagnosis of neuroblastoma (International Classification of Diseases
             for Oncology [ICD-O] morphology 9500/3) or ganglioneuroblastoma verified by histology
             or demonstration of clumps of tumor cells in bone marrow with elevated urinary
             catecholamine metabolites; patients with the following disease stages at diagnosis are
             eligible, if they meet the other specified criteria:

               -  Patients with newly diagnosed neuroblastoma with International Neuroblastoma
                  Staging System (INSS) stage 4 are eligible with the following:

                    -  v-MYC myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
                       (MYCN) amplification (&gt; 4-fold increase in MYCN signals as compared to
                       reference signals) and age &gt;= 365 days regardless of additional biologic
                       features

                    -  Age &gt; 18 months (&gt; 547 days) regardless of biologic features

                    -  Age 12-18 months (365-547 days) with any of the following 3 unfavorable
                       biologic features (MYCN amplification, unfavorable pathology and/or
                       deoxyribonucleic acid [DNA] index = 1) or any biologic feature that is
                       indeterminant/unsatisfactory/unknown

               -  Patients with newly diagnosed neuroblastoma with INSS stage 3 are eligible with
                  the following:

                    -  MYCN amplification (&gt; 4-fold increase in MYCN signals as compared to
                       reference signals), and age &gt;= 365 days, regardless of additional biologic
                       features

                    -  Age &gt; 18 months (&gt; 547 days) with unfavorable pathology, regardless of MYCN
                       status

               -  Patients with newly diagnosed INSS stage 2a/2b with MYCN amplification (&gt; 4-fold
                  increase in MYCN signals as compared to reference signals) and age &gt;= 365 days,
                  regardless of additional biologic features

               -  Patients &gt;= 365 days initially diagnosed with: INSS stage 1, 2, 4S who progressed
                  to a stage 4 without interval chemotherapy; these patients must have been
                  enrolled on ANBL00B1; it is to be noted that study enrollment must occur within 4
                  weeks of progression to stage 4 for INSS stage 1, 2, 4S

          -  Patients must have had no prior systemic therapy except for localized emergency
             radiation to sites of life-threatening or function-threatening disease and/or no more
             than 1 cycle of chemotherapy per low- or intermediate-risk neuroblastoma therapy
             (P9641, A3961, ANBL0531) prior to determination of MYCN amplification and histology

          -  Creatinine clearance or radioisotope glomerular filtration rate (GFR) &gt;= 70
             mL/min/1.73 m^2 OR serum creatinine based on age and/or gender as follows:

               -  0.6 mg/dL (1 to &lt; 2 years of age)

               -  0.8 mg/dL (2 to &lt; 6 years of age)

               -  1.0 mg/dL (6 to &lt; 10 years of age)

               -  1.2 mg/dL (10 to &lt; 13 years of age)

               -  1.5 mg/dL (male) or 1.4 mg/dL (female) (13 to &lt; 16 years of age)

               -  1.7 mg/dL (male) or 1.4 mg/dL (female) ( &gt;= 16 years of age)

          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN) for age

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
             serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) &lt; 10 x
             ULN for age

          -  Shortening fraction &gt;= 27% by echocardiogram or

          -  Ejection fraction &gt;= 50% by radionuclide evaluation

          -  No known contraindication to peripheral blood stem cell (PBSC) collection; examples of
             contraindications might be a weight or size less than the collecting institution finds
             feasible, or a physical condition that would limit the ability of the child to undergo
             apheresis catheter placement (if necessary) and/or the apheresis procedure

          -  All patients and/or their parents or legal guardians must sign a written informed
             consent

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met

        Exclusion Criteria:

          -  Females of childbearing potential must have a negative pregnancy test; patients of
             childbearing potential must agree to use an effective birth control method

          -  Female patients who are lactating must agree to stop breast-feeding

          -  Patients that are 12-18 months of age with INSS stage 4 and all 3 favorable biologic
             features (i.e., non-amplified MYCN, favorable pathology, and DNA index &gt; 1) are not
             eligible

          -  Patients are not eligible if they have received local radiation which includes any of
             the following: 1200 centigray (cGy) to more than 33% of both kidneys (patient must
             have at least 1 kidney that has not exceeded the dose/volume of radiation listed) or
             1800 cGy to more than 30% of liver and/or 900 cGy to more than 50% of liver; emergency
             local irradiation is allowed prior to study entry, provided the patient still meets
             eligibility criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Childrens Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Medical Center-Parnassus</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C S Mott Children's Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart Medical Center and Children's Hospital</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Children's Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2010</study_first_submitted>
  <study_first_submitted_qc>August 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2010</study_first_posted>
  <results_first_submitted>July 26, 2017</results_first_submitted>
  <results_first_submitted_qc>August 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 28, 2017</results_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Ganglioneuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment (131I-MIBG, Chemotherapy)</title>
          <description>Induction with multi-agent chemotherapy and MIBG labeled with iodine-131/isotretinoin/vincristine followed by Consolidation with BuMel Chemotherapy+ASCT+XRT.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment Slot Not Available</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refusal by patient/parent/guardian</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pts MIBG non-avid after enrollment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>On other COG study w/tumor tx intent</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inadequate stem cell for transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Initiation other tx prior to completion</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment (131I-MIBG, Chemotherapy)</title>
          <description>Induction with multi-agent chemotherapy and MIBG labeled with iodine-131/isotretinoin/vincristine followed by Consolidation with BuMel Chemotherapy+ASCT+XRT.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131</title>
        <description>Number of MIBG avid patients who receive 131I-MIBG divided by the number of patients evaluable for the feasibility of MIBG endpoint x 100%.</description>
        <time_frame>Up to 6 weeks after course 5 of induction</time_frame>
        <population>Includes patients who met criteria to receive 131I-MIBG but went off protocol therapy before receiving a dose assignment, but excludes patients that could not continue onto 131I-MIBG therapy due to lack of an open treatment slot. The definition of receiving MIBG labeled with iodine-131 is receiving 131I-MIBG.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (131I-MIBG, Chemotherapy)</title>
            <description>Induction with multi-agent chemotherapy and MIBG labeled with iodine-131/isotretinoin/vincristine followed by Consolidation with BuMel Chemotherapy+ASCT+XRT.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131</title>
          <description>Number of MIBG avid patients who receive 131I-MIBG divided by the number of patients evaluable for the feasibility of MIBG endpoint x 100%.</description>
          <population>Includes patients who met criteria to receive 131I-MIBG but went off protocol therapy before receiving a dose assignment, but excludes patients that could not continue onto 131I-MIBG therapy due to lack of an open treatment slot. The definition of receiving MIBG labeled with iodine-131 is receiving 131I-MIBG.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8" lower_limit="76.7" upper_limit="92.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel Chemotherapy</title>
        <description>Number of MIBG avid patients who receive 131I-MIBG and Bu/Mel divided by the number of patients evaluable for the feasibility of MIBG and Bu/Mel consolidation endpoint x 100%.</description>
        <time_frame>Up to day -6 of conditioning</time_frame>
        <population>Includes patients who met criteria to receive 131I-MIBG but went off protocol therapy before receiving a dose assignment, but excludes patients that could not receive 131I-MIBG therapy due to lack of an open treatment slot. The definition of receiving Bu/Mel conditioning is receiving the first dose of planned Busulfan on Day -6 of conditioning.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (131I-MIBG, Chemotherapy)</title>
            <description>Induction with multi-agent chemotherapy and MIBG labeled with iodine-131/isotretinoin/vincristine followed by Consolidation with BuMel Chemotherapy+ASCT+XRT.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel Chemotherapy</title>
          <description>Number of MIBG avid patients who receive 131I-MIBG and Bu/Mel divided by the number of patients evaluable for the feasibility of MIBG and Bu/Mel consolidation endpoint x 100%.</description>
          <population>Includes patients who met criteria to receive 131I-MIBG but went off protocol therapy before receiving a dose assignment, but excludes patients that could not receive 131I-MIBG therapy due to lack of an open treatment slot. The definition of receiving Bu/Mel conditioning is receiving the first dose of planned Busulfan on Day -6 of conditioning.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.2" lower_limit="68.7" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Unacceptable Toxicity and Sinusoidal Obstruction Syndrome (SOS), Assessed by Common Terminology Criteria (CTV)v.4.0 for Toxicity Assessment and Grading for I-MIBG</title>
        <description>Number of patients who had an unacceptable toxicity or experienced SOS. Unacceptable toxicity was defined as CTC Grade 4-5 Pulmonary/Respiratory.</description>
        <time_frame>Up to 6 weeks after course 5 of induction</time_frame>
        <population>Includes patients who received 131I-MIBG therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment (131I-MIBG, Chemotherapy)</title>
            <description>Induction with multi-agent chemotherapy and MIBG labeled with iodine-131/isotretinoin/vincristine followed by Consolidation with BuMel Chemotherapy+ASCT+XRT.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Unacceptable Toxicity and Sinusoidal Obstruction Syndrome (SOS), Assessed by Common Terminology Criteria (CTV)v.4.0 for Toxicity Assessment and Grading for I-MIBG</title>
          <description>Number of patients who had an unacceptable toxicity or experienced SOS. Unacceptable toxicity was defined as CTC Grade 4-5 Pulmonary/Respiratory.</description>
          <population>Includes patients who received 131I-MIBG therapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The Total Number of Participants at Risk (n=98) in the Adverse Events tables does not match the number of patients in the Participant Flow (n=99) because ineligible patients were excluded (n=1).</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment (131I-MIBG, Chemotherapy)</title>
          <description>Induction with multi-agent chemotherapy and MIBG labeled with iodine-131/isotretinoin/vincristine followed by Consolidation with BuMel Chemotherapy+ASCT+XRT.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCv4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>39000-Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>74500-Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>10300-Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>14900-Ascites</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>55600-Mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>24600-Death NOS</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>37200-General disorders and administration site conditions - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>55700-Multi-organ failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>60600-Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>21600-Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>40000-Hepatic failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>40400-Hepatic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>40600-Hepatobiliary disorders - Other specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>66500-Portal hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>44800-Infections and infestations - Other specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>53100-Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>73700-Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>10900-Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>11600-Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>15000-Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>17400-Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>45800-INR increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>88200-Weight gain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>88300-Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>10700-Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>13500-Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>41600-Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>41800-Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>42600-Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>43100-Hypokalemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>43300-Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>58000-Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>72500-Reversible posterior leukoencephalopathy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>43900-Hypoxia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>65900-Pleural effusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>69000-Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>71600-Respiratory thoracic and mediastinal disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>43600-Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCv4</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>13200-Anemia</sub_title>
                <counts group_id="E1" events="49" subjects_affected="24" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>33300-Febrile neutropenia</sub_title>
                <counts group_id="E1" events="81" subjects_affected="54" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>20000-Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>78900-Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>38900-Hearing impaired</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>10100-Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>10300-Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>14900-Ascites</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>22100-Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>25700-Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>29400-Enterocolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>36400-Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>44600-Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>55600-Mucositis oral</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>57600-Nausea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>59700-Oral pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>81900-Typhlitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>87900-Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>33900-Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>37200-General disorders and administration site conditions - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>60600-Pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>12000-Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>13100-Anaphylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>20500-Catheter related infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>25600-Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>44800-Infections and infestations - Other specify</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>53100-Lung infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>61100-Pancreas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>73700-Sepsis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>74600-Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>75200-Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>76000-Small intestine infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>82300-Upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>83100-Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>88900-Wound infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>13800-Aortic injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>45700-Injury poisoning and procedural complications - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>47300-Intraoperative hepatobiliary injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>47700-Intraoperative renal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>10900-Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>11600-Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>15000-Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>17400-Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>24100-Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>34000-Fibrinogen decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>37500-GGT increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>52600-Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>53700-Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="49" subjects_affected="21" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>58300-Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="56" subjects_affected="27" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>65800-Platelet count decreased</sub_title>
                <counts group_id="E1" events="59" subjects_affected="28" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>88200-Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>88300-Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>88500-White blood cell decreased</sub_title>
                <counts group_id="E1" events="50" subjects_affected="23" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>10700-Acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>13500-Anorexia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="33" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>24700-Dehydration</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>41300-Hypercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>41400-Hyperglycemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>41600-Hyperkalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>41700-Hypermagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>41800-Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>42600-Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>42700-Hypocalcemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>42900-Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>43100-Hypokalemia</sub_title>
                <counts group_id="E1" events="36" subjects_affected="33" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>43200-Hypomagnesemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>43300-Hyponatremia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>43500-Hypophosphatemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>54900-Metabolism and nutrition disorders - Other specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>18200-Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>37300-Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>60700-Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>10500-Abducens nerve disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>38800-Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>79100-Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>11400-Agitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>13700-Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>25400-Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>11100-Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>39300-Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>71100-Renal calculi</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>19300-Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>29700-Epistaxis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>43900-Hypoxia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>64900-Pharyngeal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>66400-Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>68700-Pulmonary edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>69000-Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>71500-Respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>78100-Stridor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>74700-Skin and subcutaneous tissue disorders - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>79000-Surgical and medical procedures - Other specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>39100-Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>42100-Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="98"/>
              </event>
              <event>
                <sub_title>43600-Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="98"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Must obtain prior approval.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Results Reporting Coordinator</name_or_title>
      <organization>Children's Oncology Group</organization>
      <phone>626-447-0064</phone>
      <email>resultsreportingcoordinator@childrensoncologygroup.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

